Long term indicators fully support a continuation of the down trend. The market is approaching oversold territory. Be watchful of a trend reversal. divergence is spotted using rsi in combination with price action which could possibly mean an uptrend may come, especially after a 25% drop to all time new lows this year. also the 20 sma has bearishly crossed over...
See link in comments for my coverage of this stock from 5/20. Stock has made it's move higher, gap filled and has found support at the 50% retracement level. Consolidation is occurring above a rising 50 EMA and the VWAP from the 2/20 peak. I would look for stock to reclaim 5 day EMA (orange) to initiate position. I have to expect further upside unless price breaks...
Price finding support above July '19 high. Strong momentum setup: OBV has set a new high, RSI showing bullish divergence while MACD has begun to accelerate. Very bullish MA convergence with 5 and 20 pushing through the 50 with upside trajectory. Notice prior move higher in late 2019 occurred subsequently to 200 MA support. Ideally I am looking for a breakout of...
SNGX: Soligenix, Inc. 2020-03-19 06:00:00 Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. engages in the development and commercialization of products to treat rare disease. It operates through the following segments: BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment offers photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous...
SGX301 Phase 3 top line data due 1Q 2020 SGX942 Phase 3 top line data due 2Q 2020 RiVax Phase 1 initiated, safety data due 2Q & 4Q 2020 Let's see if it will continue running or we can get a flag/pullback to the breakout area before entering Bias: long, wait for pullback
The daily is setting up nicely with a MACD cross and a close above the ascending trend line and the 200 MA. We could see a golden cross by EOW. 1st target $1.20 in the short term but likely much higher based on the pipeline and the multiple catalysts expected in early 2020